Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 21 for:    mexiletine

Mexiletine and Non Dystrophic Myotonias (MYOMEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02336477
Recruitment Status : Completed
First Posted : January 13, 2015
Last Update Posted : January 13, 2015
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Treatment strategies in non-dystrophic myotonias are based on selective case reports, clinical experience and theoretical benefit. Presently, the most promising antimyotonic medication is mexiletine (MEX) but its manufacturing was stopped. The proposed randomized, double-blind, placebo-controlled, crossover trial is designed to:

  1. study the safety and efficacy of mexiletine for the treatment of non-dystrophic myotonias
  2. validate electromyographic tests as a standardized outcome measure of myotonia
  3. assess the reliability and validity of a new clinical rating scale for myotonia

Condition or disease Intervention/treatment Phase
Non-dystrophic Myotonias Paramyotonia Congenita Myotonia Congenita Drug: Mexiletine Drug: placebo Phase 3

Detailed Description:

A. Specific aims

Treatment strategies in non-dystrophic myotonias are based on selective case reports, clinical experience and theoretical benefit. Presently, the most promising antimyotonic medication is mexiletine (MEX) but its manufacturing was stopped. The proposed randomized, double-blind, placebo-controlled, crossover with wash-out trial is designed to:

  • study the safety and efficacy of mexiletine for the treatment of non-dystrophic myotonias
  • validate electromyographic tests as a standardized outcome measure of myotonia
  • assess the reliability and validity of a new clinical rating scale for myotonia

B. Research design Because of their differing phenotypes, 12 Paramyotonia Congenita and 12 Myotonia Congenita subjects will be enrolled in a stratified trial

C. Outcome variables

  1. primary outcome variable: the score of stiffness severity on a self-assessment scale (100 mm VAS) measured at baseline, at the end of phase I and phase II.
  2. secondary outcome measures:

    • of efficacy:

      • standardized EMG measures after repetitive short exercise test at cold and long exercise test
      • chair test: time needed to stand up from a chair, walk around it and sit down again
      • severity and disability scale of myotonia to be validated)
      • quality of life scale (INQOL)
      • rate of drop-outs
    • of safety:

      • adverse event frequency and severity
      • EKG

D. Perspectives

It is anticipated that the trial will:

  1. provide data that justify recommendations for treatment strategies for myotonic patients
  2. provide data to justify AFSAPPS regulatory approval of mexiletine for treatment of myotonia in order to guarantee the availability of the drug for patients
  3. develop standardized diagnostic and treatment assessment for non-dystrophic myotonias

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias
Study Start Date : June 2011
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014


Arm Intervention/treatment
Experimental: 1
Mexiletine / Placebo
Drug: Mexiletine
  • Blisters of 10 capsules of 200 mg mexiletine hydrochloride.
  • Patients will receive gradual dose of the treatment as it would be done in clinical practice.
  • Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.
  • The duration of each treatment period is 18 days minimum (maximum 22 days).

Drug: placebo
Experimental: 2
Placebo / Mexiletine
Drug: Mexiletine
  • Blisters of 10 capsules of 200 mg mexiletine hydrochloride.
  • Patients will receive gradual dose of the treatment as it would be done in clinical practice.
  • Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.
  • The duration of each treatment period is 18 days minimum (maximum 22 days).

Drug: placebo



Primary Outcome Measures :
  1. score of stiffness severity on a self-assessment scale (100 mm VAS) [ Time Frame: 18 days ]

Secondary Outcome Measures :
  1. standardized EMG measures after repetitive short exercise test at cold and long exercise test [ Time Frame: 18 days ]
  2. chair test: time needed to stand up from a chair, walk around it and sit down again [ Time Frame: 18 days ]
  3. severity and disability scale of myotonia to be validated [ Time Frame: 18 days ]
  4. quality of life scale (INQOL) [ Time Frame: 18 days ]
  5. CGI efficacy (Clinical Global Impression- Efficacy index) [ Time Frame: 18 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • Genetically definite MC and PC.
  • Male and female participants, age between 18 and 65 who are able to comply with the study conditions.
  • Participants who experience myotonic symptoms severe enough to justify treatment.

The severity will be evaluated on:

  • Clinical criteria: myotonia is considered as severe if it involves at least two segments (upper limb, lower limb or face)
  • Disabling criteria: myotonia is considered severe if patients notice impacts on at least 3 of the 7 daily activities listed in the disabling section of the clinical myotonia scale (Annex 2).

Thus, patients who experience myotonic symptoms severe enough to justify treatment are those with myotonia that involves at least two segments and that have an impact on at least 3 daily activities.

  • Participants who are drug naive or those who receiving mexiletine at Effective dosage and agreeing to stop treatment at least four days before inclusion .
  • Pregnancy: Women: non-childbearing potential (i.e., postmenopausal or Surgically sterile) or must use a medically accepted contraceptive regimen; a pregnancy test will ensure that they are not pregnant.
  • Normal cardiac exam performed by a cardiologist including EKG, and Cardiac ultrasound (if not done within 3 months before trial).

Exclusion criteria :

  • Intercurrent event which could interfere with the muscle function (infection,trauma, fracture, …)
  • Coincidental renal, hepatic, respiratory, thyroid, other neuromuscular disease or heart disease that will contraindicate mexiletine or interfere with clinical evaluation.
  • Use of any of the following medications that can interfere with muscle function :diuretics, anti epileptics (sodium channel blockers), antiarrhythmics, corticosteroids, beta-blockers,
  • Allergy to mexiletine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02336477


Locations
Layout table for location information
France
Groupe Hospitalier Pitié Salpetriere
Paris, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Bertrand Fontaine, MD, PhD Assistance Publique - Hôpitaux de Paris
Principal Investigator: Savine Vicart, MD Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02336477     History of Changes
Other Study ID Numbers: P091101
First Posted: January 13, 2015    Key Record Dates
Last Update Posted: January 13, 2015
Last Verified: January 2015
Keywords provided by Assistance Publique - Hôpitaux de Paris:
non-dystrophic myotonias
paramyotonia congenita
myotonia congenita
Mexiletine
Randomized clinical trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Mexiletine
Myotonia Congenita
Myotonic Disorders
Myotonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Neuromuscular Diseases
Genetic Diseases, Inborn
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action